Founded in 2015, Allianz Pharmascience is a research-driven biopharmaceutical company developing first-in-class small molecules that targets three main therapeutic areas: neurodegenerative diseases, inflammatory disorders, and cancers. The choices of therapeutic targets are mechanistically driven based on cellular redox homeostasis, especially through the activation of the nuclear factor (erythroid-derived 2)-like 2 (NFE2L2/Nrf2) pathway.